It was found that the drug may act on the AGE-RAGE signaling pathway through 15 targets, on the HIF-1 signaling pathway through 15 targets, and on the IL-17 signaling pathway through 11 targets to exert anti-NAFLD effects. Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.